Page 15 - Read Online

Baker et al. J Cancer Metastasis Treat 2020;6:24 I http://dx.doi.org/10.20517/2394-4722.2020.36 Page 11 of 12

REFERENCES
1. O’Bryan RM, Luce JK, Talley RW, Gottlieb JA, Baker LH, et al. Phase II evaluation of adriamycin in human neoplasia. Cancer
1973;32:1-8.
2. Benjamin RS, Wiernik PH, Bachur NR. Adriamycin chemotherapy--efficacy, safety, and pharmacologic basis of an intermittent single
high-dosage schedule. Cancer 1974;33:19-27.
3. Von Hoff DD, Rozencweig M, Layard M, Slavik M, Muggia FM. Daunomycin-induced cardiotoxicity in children and adults: a review of
110 cases. Am J Med 1977;62:200-8.
4. Zalupski M, Metch B, Balcerzak S, Fletcher WS, Chapman R, et al. Phase III comparison of doxorubicin and dacarbazine given by bolus
versus infusion in patients with soft-tissue sarcomas: a Southwest Oncology Group study. J Natl Cancer Inst 1991;83:926-32.
5. Oeffinger KC, Mertens AC, Sklar CA, Kawashima T, Hudson MM, et al. Chronic health conditions in adult survivors of childhood
cancer. N Engl J Med 2006;355:1572-82.
6. Armstrong GT, Liu Q, Yasui Y, Neglia JP, Leisenring W, et al. Late mortality among 5-year survivors of childhood cancer: a summary
from the Childhood Cancer Survivor Study. J Clin Oncol 2009;27:2328-38.
7. Armenian SH, Armstrong GT, Aune G, Chow EJ, Ehrhardt MJ, et al. Cardiovascular disease in survivors of childhood cancer: insights
into epidemiology, pathophysiology, and prevention. J Clin Oncol 2018;36:2135-44.
8. Gibson TM, Mostoufi-Moab S, Stratton KL, Leisenring WM, Barnea D, et al. Temporal patterns in the risk of chronic health conditions
in survivors of childhood cancer diagnosed 1970-99: a report from the Childhood Cancer Survivor Study cohort. Lancet Oncol
2018;19:1590-601.
9. Bagnasco F, Caruso S, Andreano A, Valsecchi MG, Jankovic M, et al. Late mortality and causes of death among 5-year survivors of
childhood cancer diagnosed in the period 1960-1999 and registered in the Italian Off-Therapy Registry. Eur J Cancer 2019;110:86-97.
10. Chatterjee K, Zhang J, Honbo N, Karliner JS. Doxorubicin cardiomyopathy. Cardiology 2010;115:155-62.
11. Rosenberg SA, De_Vita VT, Lawrence TS. DeVita, Hellman, and Rosenberg's Cancer: Principles & Practice of Oncology. 11th ed.
Lippincott, Williams & Wilkins; 2015.
12. Chow EJ, Chen Y, Hudson MM, Feijen EAM, Kremer LC, et al. Prediction of ischemic heart disease and stroke in survivors of childhood
cancer. J Clin Oncol 2018;36:44-52.
13. Armstrong GT, Oeffinger KC, Chen Y, Kawashima T, Yasui Y, et al. Modifiable risk factors and major cardiac events among adult
survivors of childhood cancer. J Clin Oncol 2013;31:3673-80.
14. Ridker PM, Everett BM, Thuren T, MacFadyen JG, Chang WH, et al. Antiinflammatory therapy with canakinumab for atherosclerotic
disease. N Engl J Med 2017;377:1119-31.
15. Chen Y, Chow EJ, Oeffinger KC, Border WL, Leisenring WM, et al. Traditional cardiovascular risk factors and individual prediction of
cardiovascular events in childhood cancer survivors. J Natl Cancer Inst 2020;112:256-65.
16. Blaes AH, Shenoy C. Is it time to include cancer in cardiovascular risk prediction tools? Lancet 2019;394:986-8.
17. Ridker PM, MacFadyen JG, Everett BM, Libby P, Thuren T, et al. Relationship of C-reactive protein reduction to cardiovascular
event reduction following treatment with canakinumab: a secondary analysis from the CANTOS randomised controlled trial. Lancet
2018;391:319-28.
18. Ridker PM, MacFadyen JG, Thuren T, Everett BM, Libby P, et al. Effect of interleukin-1beta inhibition with canakinumab on incident
lung cancer in patients with atherosclerosis: exploratory results from a randomised, double-blind, placebo-controlled trial. Lancet
2017;390:1833-42.
19. Arnett DK, Blumenthal RS, Albert MA, Buroker AB, Goldberger ZD, et al. 2019 ACC/AHA Guideline on the Primary Prevention of
Cardiovascular Disease: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force
on Clinical Practice Guidelines. J Am Coll Cardiol 2019;74:1376-414.
20. Grundy SM, Stone NJ, Bailey AL, Beam C, Birtcher KK, et al. 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/
ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol: A Report of the American College of Cardiology/American
Heart Association Task Force on Clinical Practice Guidelines. Circulation 2019;139:e1082-143.
21. Ganz PA, Goodwin PJ. Breast cancer survivorship: where are we today? In: Ganz PA, editor. Improving Outcomes for Breast Cancer
Survivors: Perspectives on Research Challenges and Opportunities. Cham: Springer International Publishing; 2015. pp. 1-8.
22. Jacobs LA, Shulman LN. Follow-up care of cancer survivors: challenges and solutions. Lancet Oncol 2017;18:e19-29.
23. Rokitka DA, Curtin C, Heffler JE, Zevon MA, Attwood K, et al. Patterns of loss to follow-up care among childhood cancer survivors. J
Adolesc Young Adult Oncol 2017;6:67-73.
24. Suh E, Daugherty CK, Wroblewski K, Lee H, Kigin ML, et al. General internists’ preferences and knowledge about the care of adult
survivors of childhood cancer: a cross-sectional survey. An Intern Med 2014;160:11-7.
25. Nathan PC, Daugherty CK, Wroblewski KE, Kigin ML, Stewart TV, et al. Family physician preferences and knowledge gaps regarding
the care of adolescent and young adult survivors of childhood cancer. J cancer Surviv 2013;7:275-82.
26. Bobowski NP, Baker LH. The university of michigan sarcoma survivorship clinic: preventing, diagnosing, and treating chronic illness for
improved survival and long-term health. J Adolesc Young Adult Oncol 2016;5:211-4.
27. D’Agostino RB, Vasan RS, Pencina MJ, Wolf PA, Cobain M, et al. General cardiovascular risk profile for use in primary care: the
framingham heart study. Circulation 2008;117:743-53.
28. Ridker PM, Paynter NP, Rifai N, Gaziano JM, Cook NR. C-reactive protein and parental history improve global cardiovascular risk
prediction: the Reynolds Risk Score for men. Circulation 2008;118:2243-51.
29. Orimoloye OA, Mirbolouk M, Uddin SMI, Dardari ZA, Miedema MD, et al. Association between self-rated health, coronary artery